The UAE Ministry of Health and Prevention (MoHAP) has recently signed an agreement with Bayer Middle East and Axios Health Education Services to provide a one-year medication for multiple sclerosis (MS) patients.

The MoU, part of ‘Da’m’ initiative (Support) launched by MoHAP in 2018, will also cater to patients with pulmonary arterial hypertension (PAH), and patients with chronic thromboembolic pulmonary hypertension (CTEPH), whose medical insurance doesn’t cover the total cost of treatment, said a statement from MoHAP.

The agreement was signed by Dr Amin Hussein Al Amiri, assistant undersecretary of the ministry’s Public Health Policy and Licenses; Henrik Wulff, managing director, Bayer Middle East; and Anas Al Safarini, executive director for the Middle East and North Africa, Axios Health Education Services.

Dr Ruqaya Al Bastaki, director of Drug Department MoHAP, pointed to the importance of renewing the initiative for the second consecutive year, as part of the authority’s keenness on mitigating patient’s suffering, especially whose insurance is not covering the total cost of treatment and improve their commitment to the prescribed treatment plan.

The MoU also covers non-insured patients or those with partial insurance coverage, it said.

Henrik Wulff, managing director, Bayer Middle East, emphasised the company’s keenness on bolstering MoHAP’s efforts in providing MS patients, patients with PAH, and patients with CTEPH to ensure their adherence to treatment plans.

Al Safarini highlighted the importance of renewing the agreement, stressing Axios’ commitment to coordinate with charities and programme partners to ensure the seamless progress of the programme.

"It is important to manage patient’s treatment journey through the constant communication and ensure that they regularly receive the medication according to their treatment plan, he added.-TradeArabia News Service